Caribou Biosciences vs Lineage Cell Therapeutics
CRBU and LCTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CRBU and LCTX compare
Lineage Cell Therapeutics is the larger company, worth 6.0 times as much as Caribou Biosciences ($231M against $38.8M).
Caribou Biosciences grew revenue faster over the last twelve months (1.6% versus 0.18% for Lineage Cell Therapeutics).
Lineage Cell Therapeutics keeps more of each dollar of sales as profit, with a net margin of 16.2% compared with −1085% at Caribou Biosciences.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CRBU | LCTX |
|---|---|---|
| Size and price | ||
| Market cap | $38.8M | $231M |
| Share price | $0.362 | $0.915 |
| Change, 1 year | −84.0% | −52.6% |
| Change, 5 years | −98.3% | −60.1% |
| Beta (5Y) | 1.94 | 0.96 |
| Employees | 97 | 77 |
| StockData Score | ||
| Total score | 8 | 8 |
| Valuation score | 3 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 3 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 4.1× (better) | 21.3× |
| P/B | 0.5× (better) | 3.4× |
| FCF yield | −240% | −11.4% (better) |
| Fair value | $1.08 | $0.620 |
| Margin of safety | 66.4% (better) | −47.6% |
| Growth | ||
| Revenue growth (TTM) | 1.6% (better) | 0.18% |
| Revenue growth, 5Y average | −2.0% | 51.5% (better) |
| Profitability | ||
| Operating margin | −1141% | −280% (better) |
| Net margin | −1085% | 16.2% (better) |
| FCF margin | −985% | −244% (better) |
| Return on equity | −93.8% | 3.9% (better) |
| Return on invested capital | – | −1395% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 4.97 | 5.96 (better) |
| Altman Z-score | −9.18 | −2.87 (better) |
| Piotroski F-score | 2 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | −69.3% | – |
| Shareholder yield | −69.3% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 45.5% | 46.1% |
| Held by insiders | 5.7% | 74.4% |
| Insider net buying, 12 months | −$47.5K | $24.4K (better) |
| Short interest, % of float | 14.7% | 37.7% |
Go deeper
- CRBU stock overview
- CRBU income statement
- CRBU valuation and score
- LCTX stock overview
- LCTX income statement
- LCTX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.